Literature DB >> 11549873

Clinical and endocrine characteristics in atypical and classical growth hormone insensitivity syndrome.

C P Burren1, K A Woods, S J Rose, M Tauber, D A Price, U Heinrich, G Gilli, M Razzaghy-Azar, A Al-Ashwal, P A Crock, P Rochiccioli, N Yordam, M B Ranke, P G Chatelain, M A Preece, R G Rosenfeld, M O Savage.   

Abstract

OBJECTIVE: Classical growth hormone insensitivity syndrome (GHIS) comprises a dysmorphic phenotype, extreme short stature (height SDS < 3), normal GH and low IGF-I and IGFBP-3. Wide clinical variation is recognised with classical and atypical forms. We aimed to delineate features of the milder "atypical" GHIS phenotype, and to determine whether this correlates with milder auxological and biochemical features.
METHODS: Fifty-nine patients from a European series of 82 patients with GHIS, with strict diagnostic criteria of GHIS, were studied and assigned to classical or atypical GHIS groups according to facial phenotype, i.e. "classical" required 2 of 3 recognized GHIS features (frontal bossing, mid-facial hypoplasia and depressed nasal bridge), "atypical" required 0 or 1 of these facial features. Classical and atypical GHIS groups were compared in terms of (1) phenotypic features, including high-pitched voice, sparse hair, blue sclera, hypoglycaemia, microphallus, (2) birth length, height SDS, and (3) basal IGF-I, IGF-II, IGFBP-1, IGFBP-3, GHBP and increase in IGF-I on IGF-I generation testing.
RESULTS: Fifty patients [24 males, 26 females, aged 8.6 +/- 4.6 years (mean +/- SD)] had "classical GHIS", 9 patients (7 males, 2 females, aged 7.8 +/- 4.1 years) had "atypical GHIS", 7 with normal facies. Atypical GHIS patients had lesser height deficit (Ht SDS -4.0 +/- 1.4) compared to classical GHIS (-6.7 +/- 1.4), less reduction in IGFBP-3 SDS (atypical -5.5 +/- 3.3; classical -8.6 +/- 2.4), and more had normal GHBP (>10% binding). Other variables were also less frequent in atypical GHIS patients: high-pitched voice 11% (70% classical), sparse hair 11% (42% classical), blue sclera 0% (38% classical), hypoglycaemia 11% (42% classical), and microphallus 14% (1 of 7 males), compared to 79% of classical (19 of 24 males).
CONCLUSIONS: Atypical GHIS patients, with relatively normal facial appearance, demonstrate less height defect and biochemical abnormalities compared to classical patients. GH insensitivity may be present in children with short stature and an otherwise normal appearance. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549873     DOI: 10.1159/000049983

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  8 in total

Review 1.  Growth hormone insensitivity: diagnostic and therapeutic approaches.

Authors:  S Kurtoğlu; N Hatipoglu
Journal:  J Endocrinol Invest       Date:  2015-06-11       Impact factor: 4.256

Review 2.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

3.  Analysis of voice in patients with untreated active acromegaly.

Authors:  F Bogazzi; A Nacci; A Campomori; R La Vela; G Rossi; M Lombardi; B Fattori; L Bartalena; F Ursino; E Martino
Journal:  J Endocrinol Invest       Date:  2010-03       Impact factor: 4.256

Review 4.  Controversies in the definition and treatment of idiopathic short stature (ISS).

Authors:  Stefania Pedicelli; Emanuela Peschiaroli; Enrica Violi; Stefano Cianfarani
Journal:  J Clin Res Pediatr Endocrinol       Date:  2009-02-01

5.  Clinical features and endocrine profile of Laron syndrome in Indian children.

Authors:  Supriya R Phanse-Gupte; Vaman V Khadilkar; Anuradha V Khadilkar
Journal:  Indian J Endocrinol Metab       Date:  2014-11

6.  Baseline IGFBP - 3 as the Key Element to Predict Growth Response to Growth Hormone and IGF - 1 Therapy in Subjects with Non - GH Deficient Short Stature and IGF - 1 Deficiency.

Authors:  Sheila Perez-Colon; Oksana Lazareva; Radhika Purushothaman; Shahid Malik; Svetlana Ten; Amrit Bhangoo
Journal:  Int J Endocrinol Metab       Date:  2018-05-21

7.  Identification and characterisation of a novel GHR defect disrupting the polypyrimidine tract and resulting in GH insensitivity.

Authors:  A David; F Miraki-Moud; N J Shaw; M O Savage; A J L Clark; L A Metherell
Journal:  Eur J Endocrinol       Date:  2009-10-07       Impact factor: 6.664

8.  Role of the GH-IGF1 axis on the hypothalamus-pituitary-testicular axis function: lessons from Laron syndrome.

Authors:  Rossella Cannarella; Andrea Crafa; Sandro La Vignera; Rosita A Condorelli; Aldo E Calogero
Journal:  Endocr Connect       Date:  2021-08-25       Impact factor: 3.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.